Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Protocol: Perioperative Serplulimab with Chemotherapy for PD-L1 Positive Gastric Cancer
This phase 3 study demonstrated that neoadjuvant serplulimab plus chemotherapy followed by adjuvant serplulimab significantly improved event-free survival compared with perioperati
New Protocol: Sacituzumab Tirumotecan with Pembrolizumab for PD-L1 Positive Advanced NSCLC
The OptiTROP-Lung05 phase 3 trial demonstrated that sacituzumab tirumotecan combined with pembrolizumab significantly improved progression-free survival and objective response rate
New Reference: Perioperative Pembrolizumab for MSI-H/dMMR Colorectal Cancer
In this phase II trial of patients with localized dMMR/MSI colorectal cancer, perioperative pembrolizumab achieved a pathologic complete response rate of 53%. Treatment was feasibl
New Reference: Ivonescimab with Chemotherapy for Advanced Squamous NSCLC
In this phase 3 trial for advanced squamous non-small-cell lung cancer, ivonescimab plus chemotherapy significantly improved overall survival compared to tislelizumab plus chemothe
New Indication: Duvelisib for Peripheral T-Cell Lymphoma
This phase II PRIMO trial demonstrated that duvelisib monotherapy has significant clinical activity in heavily pretreated relapsed/refractory peripheral T-cell lymphoma, with an ov
New Protocol: Datopotamab deruxtecan with Durvalumab for Triple-Negative Breast Cancer
This phase Ib/II BEGONIA study evaluated first-line datopotamab deruxtecan combined with durvalumab in unresectable locally advanced or metastatic triple-negative breast cancer. Th
New Drug: Daraxonrasib for Previously Treated Pancreatic Cancer
In this phase 3 randomized trial in patients with previously treated metastatic pancreatic ductal adenocarcinoma, treatment with daraxonrasib significantly improved overall surviva
New Reference: Carboplatin Addition to (Neo)Adjuvant Therapy in Triple-Negative Breast Cancer
In this phase 3 trial of early-stage triple-negative breast cancer, adding carboplatin to taxanes significantly improved 5-year event-free survival with a hazard ratio of 0.67. The
New Reference: Perioperative Apalutamide in High-Risk Localized Prostate Cancer
In this phase 3 trial in patients with high-risk localized or locally advanced prostate cancer, perioperative treatment with ADT plus apalutamide significantly improved pathologica
